Expanded Access Use of Derazantinib for Advanced Intrahepatic Cholangiocarcinoma (iCCA) With FGFR Genomic Alterations

Inclusion Criteria

• •all other treatment options had been exhausted
• •patient was ineligible for any ongoing trials or was geographically inaccessible to trials including a trial with derazantinib
• •there was a reason to believe that the potential benefit of receiving derazantinib outweighs the risk of treatment with an investigational drug product
• •patient was willing and able to provide written informed consent
• •if applicable, regulatory approval by the appropriate jurisdiction was obtained